ProMIS Neurosciences Inc.

For the period ended Mar 31, 2026. Filed May 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 12, 2026

PMN$4.05-2.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets


· · March 31, · · December 31, ·
· · 2026 · · 2025 ·
Assets
Current assets:
Cash	$63,814,345	$6,116,556
Short-term investments	33,753	33,753
Prepaid expenses and other current assets	1,764,594	3,032,112
Total current assets	65,612,692	9,182,421
Prepaid expenses, long-term	1,798,879	—
Total assets	$67,411,571	$9,182,421
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable	$1,716,823	$2,543,415
Accrued liabilities	4,897,796	7,868,416
Total current liabilities	6,614,619	10,411,831
Share-based compensation liability	79,380	29,182
Total liabilities	6,693,999	10,441,013

Shareholders' equity:
Common Shares, no par value, unlimited shares authorized, 8,967,693 and 2,152,397 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	—	—
Additional paid-in capital	199,739,348	129,518,812
Accumulated other comprehensive loss	(371,184)	(371,184)
Accumulated deficit	(138,650,592)	(130,406,220)
Total shareholders' equity	60,717,572	(1,258,592)
Total liabilities and shareholders' equity	$67,411,571	$9,182,421

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.